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Abstract
Basic investigations link a Val158Met polymorphism (rs4680) in the catechol-O-methyl-
transferase (COMT) gene to not only its enzymatic activity, but also to its dopaminergic tone
in the prefrontal cortex. Previous PET studies have documented the relationship between
COMT Val158Met polymorphism and D1 and D2/3 receptor binding potential (BP), and inter-
preted them in terms of dopaminergic tone. The use of baseline dopamine D1 and D2/3
receptor binding potential (BPND) as a proxy for dopaminergic tone is problematic because
they reflect both endogenous dopamine levels (a change in radiotracer's apparent affinity)
and receptor density. In this analysis of 31 healthy controls genotyped for the Val158Met
polymorphism (Val/Val, Val/Met, and Met/Met), we used amphetamine-induced displace-
ment of [11C]FLB 457 as a direct measure of dopamine release. Our analysis failed to show
a relationship between COMT genotype status and prefrontal cortical dopamine release.
COMT genotype was also not predictive of baseline dopamine D2/3 receptor BPND.
Introduction
Previous studies have demonstrated that the catabolic enzyme catechol-O-methyltransferase
(COMT) plays a major role in regulating dopamine transmission in the prefrontal cortex, a
region that is relatively devoid of dopamine reuptake transporters, compared to the striatum
[1, 2]. Human studies also link the functional polymorphism Val158Met (rs4680) in the
COMT gene to changes in COMT enzymatic activity. The Met allele resulting from a G>A
substitution is associated with reduced COMT enzyme activity in the brain, compared with
the Val allele [3]. This has led investigators to postulate that lower and higher COMT activity,
as determined by the COMT genotype in individuals, underlies increased and decreased
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dopaminergic tone, respectively, in the prefrontal cortex (dopamine levels in Met/Met>Met/
Val> Val/Val) [4]. These data have led to studies investigating the relationship between
COMT Val158Met genotype and dopamine D1 and D2/3 receptor binding potential, BPND [5,
6]. The results of these COMT genotype studies, in which baseline dopamine D1 and D2/3
receptor BPND were used as a proxy for endogenous dopamine tone, are inconsistent. In a
study of 28 healthy controls with [11C]NNC 112 and PET, Slifstein et al., reported that Val
homozygotes had higher D1 receptor BP compared to Met carriers and homozygotes in cortical
regions. Higher D1 receptor BPND in the cortex of Val/Val subjects compared to Met carriers
in this study was interpreted as a marker of decreased dopamine. Such an interpretation is con-
sistent with the notion that COMT clears cortical dopamine ~40% more efficiently in individu-
als with the COMT Val compared to the Met allele [7]. However, in a study of 38 healthy
controls with the dopamine D2/3 antagonist radiotracer [
11C]FLB 457 and PET, Hirvonen and
colleagues found no significant association between the Val158Met genotype and cortical D2/3
receptor BPND. The reason for the discrepant results observed with [
11C]NNC 112 and [11C]
FLB 457, which are both reportedly sensitive to chronic alterations in endogenous dopamine
(despite the fact that they label different subtypes of the dopamine receptor), is unclear [8, 9]. It
is possible that the relatively low signal to noise ratio for [11C]FLB 457 in the cortex makes its
baseline BPND a less than ideal proxy for endogenous dopamine tone. It is also possible that
Val158Met has an effect on D1 receptor BPND that is independent of endogenous dopamine
levels, and this is not necessarily reflected in the D2/3 receptor BPND. The use of D1 and D2/3
receptor BPND as a proxy to interpret vivo dopamine levels in these prior studies complicates
the interpretation of these data.
Recent studies with [11C]FLB 457 and PET have demonstrated the ability to measure dopa-
mine transmission in the prefrontal cortex following an acute amphetamine challenge [9–11].
In human studies, amphetamine leads to a 5 to 13% reduction in [11C]FLB 457 BPND in several
cortical regions of interest including the dorsolateral prefrontal cortex, orbital frontal cortex,
medial prefrontal cortex, and anterior cingulate cortex. This reduction in [11C]FLB 457 BPND
following an amphetamine challenge has been shown to linearly correlate with increases in
extracellular fluid dopamine as measured using microdialysis in non-human primates [12].
The ability to measure amphetamine-induced displacement of [11C]FLB 457 with PET pro-
vides an opportunity to test the relationship between dopamine transmission and COMT
Val158Met genotype status. Here, we include data from a cohort of healthy controls who
underwent [11C]FLB 457 PET scans before and after an acute oral amphetamine challenge (0.5
mg/kg). In this dataset, the relationship between COMT Val158Met genotype status and corti-
cal [11C]FLB 457 BPND, as well as amphetamine-induced dopamine release (i.e., change in
[11C]FLB 457 BPND following an acute amphetamine challenge, ΔBPND), were examined.
Based on the literature, we hypothesized that the COMT Val158Met genotype would be predic-
tive of amphetamine-induced ΔBPND (Met/Met> Val/Met> Val/Val), but not baseline D2/3
receptor BPND in cortical regions.
Materials and Methods
Ethics statement
The Institutional Review Board and Radioactive Drug Research Committee of the University
of Pittsburgh approved the study. All subjects provided written informed consent.
Participants
Data were acquired following written informed consent in a protocol approved by both the Uni-
versity of Pittsburgh Institutional Review Board and the Radioactive Drug Research Committee.
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Amphetamine-induced displacement of [11C]FLB 457 BPND and COMTVal158Met genotyping
(Val/Val, Val/Met, Met/Met) were available for n = 31 healthy control (8 females/23 males; 2
Asian/4 African American/25 Caucasian; see Table 1 for detailed demographics). Imaging data
from 17/31 subjects were previously published [19]
Inclusion/Exclusion criteria
Study criteria for inclusion was 1) male or female aged 18–40 years; 2) no current or past
DSM-IV axis I disorder as assessed by the Structured Clinical Interview for DSM-IV Axis I Dis-
orders; 3) no current use of cocaine, opiates, cannabis, sedative-hypnotics, amphetamines,
3,4-methylenedioxy-N-methylamphetamine, or phencyclidine (as confirmed by urine drug
screen at the study screening and PET scan day); 4) not currently pregnant or nursing; 5) no
current or past chronic medical or neurological illnesses as assessed by a complete physical
examination and laboratory examination; 6) no resting systolic blood pressure>140 mm Hg
and no diastolic blood pressure>90 mm Hg; 7) no history of prior radioactivity exposure from
nuclear medicine studies or occupation; 8) no metallic objects in the body that are contraindi-
cated for MRI; 9) no more than one risk factor for coronary artery disease (e.g., smoking, high
cholesterol, sedentary lifestyle, diabetes, hypertension, obesity, etc.); 10) no first-degree relative
with a psychotic or mood disorder; and 11) not currently on any prescription or over-the-
counter medications.
Image Acquisition and Analysis
Amagnetization prepared rapid gradient echo structural MRI scan was obtained using a Sie-
mens 3 Tesla Trio scanner for determination of regions of interest. All but eight subjects under-
went the baseline and post-amphetamine [11C]FLB 457 PET scan on the same day. In the
remaining subjects, the baseline and post-amphetamine scans were acquired on different days,
approximately a week apart. The details of this imaging protocol have been published [9].
Briefly, [11C]FLB 457 was synthesized using the methodology reported by Halldin, et al.
[13]. PET imaging sessions were conducted with the ECAT EXACT HR+ camera. Following a
transmission scan, subjects received an intravenous bolus injection of [11C]FLB 457 and emis-
sion data was collected for 90 minutes. Arterial blood samples were collected to measure the
plasma free fraction (fP) for [
11C]FLB 457 and derive a metabolite corrected arterial input func-
tion for modeling using methods described previously [9]. The maximum injected mass for
[11C]FLB 457 was restricted to 0.6 μg [14]. The post-amphetamine [11C]FLB 457 scan was
performed ~ 3 to 4.5 hours after the administration of 0.5 mg kg-1 of oral d-amphetamine.
Amphetamine blood levels were measured before the post-amphetamine [11C]FLB 457 PET
scan and were analyzed using methods previously described [15].
PET data were reconstructed and processed with the image analysis software MEDx (Sensor
Systems, Inc., Sterling, Virginia) and SPM2 (www.fil.ion.ucl.ac.uk/spm) as described in [9].
Frame-to-frame motion correction for head movement and MR-PET image alignment were
performed using a mutual information algorithm implemented in SPM2. Time activity curves
were generated in MEDx for the eight cortical regions of interest and cerebellum (reference
region) by using the criteria and methods previously described [9, 16]. Sampled cortical regions
(n = 8) included the medial temporal lobe (MTL), dorsolateral prefrontal cortex (DLPFC),
orbital frontal cortex (OFC), medial prefrontal cortex (MPFC), anterior cingulate cortex
(ACC), temporal cortex (TEMP), parietal cortex (PAR), and occipital cortex (OCC). Deriva-
tion of [11C]FLB 457 VT in the regions of interest (VT ROI) and cerebellum (VND) was per-
formed using a two-tissue compartment kinetic analysis using the arterial input function as
previously described [9].
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PET outcome variables are defined in accordance to the consensus nomenclature for in vivo
imaging of reversibly binding radioligands [17]. D2/3 receptor availability at baseline and post-
amphetamine was estimated using BPND, i.e., binding potential relative to non-displaceable
uptake, which was derived as
BPND ¼
VT ROI  VND
VND
¼ fND 
Bavail
KD
ð1Þ
where, fND represents the free fraction of [
11C]FLB 457 in the non-displaceable compartment,
Bavail is the density of D2/3 receptors (nmol L
-1) available to bind [11C]FLB 457 in vivo, KD is
the in vivo equilibrium dissociation constant of [11C]FLB 457 (nmol L-1)
The amphetamine-induced change in BPND (Δ BPND) was calculated as the difference
between BPND measured in the post-amphetamine condition (BPND AMPH) and BPND mea-
sured in the baseline condition (BPND BASE), and expressed as a percentage of BPND BASE
DBPND ¼ 100 
BPND AMPH  BPND BASE
BPND BASE
ð2Þ
COMT (Val/Met) Genotypes
DNA was extracted from frozen blood samples of subjects using the QIAMP DNA Blood Mini
Kit. DNA was diluted to working stock (10ng ul-1). PCR primers were designed around COMT
rs4680 (G/A polymorphism) using PRIMER3 program (http://bioinfo.ut.ee/primer3-0.4.0/).
The size of the amplicon is 348bp. The primer sequences are F- GGGCCTACTGTGGCTACTCA
and R-CTTGGCAGTTTACCCAGAGC. PCR conditions were 94° for 10 minutes, followed by 35
cycles of 94° for 30 seconds, 54° for 30 seconds 72° for 30 seconds, and final extension at 72°
for 7 minutes. PCR products were checked on 1.5% agarose gel. After gel checks, PCR products
were treated with ExoSAP-IT and DNA sequencing was conducted using the BigDye Termina-
tor V3.1 Cycle Sequencing Kit (Life Technologies). Sequencing traces were compiled on
Sequencher V5.3 and two investigators read genotypes traces separately to confirm them. Dis-
crepancies were resolved through re-analysis.
Statistical Analysis
Group wise differences in demographics were tested using Chi-squared and analysis of variance
(as applicable). Comparison between baseline and post-amphetamine scan variables (injected
dose, specific activity, injected mass, free fraction in plasma, clearance and cerebellum VND) were
performed with paired t-tests. Prior to performing statistical tests, Box's M tests were performed
on the dependent variables, BPND and ΔBPND, to evaluate the data, where p>0.05. Thus, geno-
type effect on baseline cortical BPND and Δ BPND was tested using a linear mixed model analysis
Table 1. Demographics of the clinical sample.
Val/Val Val/Met Met/Met p value
N (%) 11 (35.5%) 14 (45.2%) 6 (19.3%)
Gender (% females) 9M/2F (18%) 10M/4F (29%) 4M/2F (33%) 0.75
Ethnicity 2AA/8C/1Other 1AA/12C/1Other 1AA/5C/0Other 0.86
Smoking Status (% smokers) 7 Yes / 4 No (64%) 8 Yes / 6 No (57%) 1 Yes / 5 No (17%) 0.15
Age (years) 26 ± 4 26 ± 5 25 ± 4 0.82
Weight (kg) 76.4 ± 11.4 75.4 ± 10.4 72.1 ± 12.7 0.75
doi:10.1371/journal.pone.0157867.t001
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with cortical regions of interest as a repeated measure and genotype as the fixed factor (IBM
SPSS Statistics). Genotype, region, and genotype by region interaction were included in the
model as explanatory variables. To control for the potential confounding effect of smoking status,
its effect on the model was evaluated by including it as a factor following the primary analysis. A
two-tailed probability value of p< 0.05 was selected as the significance level for all analyses.
Results
Demographic and scan parameters
Genotype frequencies, age, sex, ethnicity, smoking status and weight are included in Table 1.
The genotype distribution is consistent with Hardy Weinberg expectations. The allele fre-
quency in the sample was consistent with estimates among individuals with Caucasian ancestry
[18]. No significant differences were noted in any of these variables (smoking status was at
p = 0.15, however, the reliability of this test was low due to there being only one smoker in the
Met/Met group). Table 2 shows no significant differences in the baseline and post-amphet-
amine [11C]FLB 457 scan parameters in all three genotype groups. No significant differences
were noted in the genotyped groups in the amphetamine blood levels measured at time, t = 0
min relative to post-amphetamine [11C]FLB 457 scan (data in Table 2).
D2/3 receptor availability (BPND) under baseline conditions
As shown in Fig 1, no differences in baseline [11C]FLB 457 BPND were observed between the
genotypes (linear mixed model, effect of genotype, F (2, 28) = 0.04, p = 0.96; effect of region,
F (7, 196) = 186.96, p< 0.001; genotype x region interaction, F (14, 196) = 0.39, p = 0.98). The
inclusion of smoking as a factor in the model did not alter the results (genotype, p = 0.96; gen-
otype region interaction, p = 0.85). BPND derived using a simplified reference tissue method
with the cerebellum as an input function did not alter the results (genotype, p = 0.94; region,
p<0.001; genotyperegion interaction, p = 0.94)
Amphetamine-induced reduction in D2/3 receptor availability (Δ BPND)
Consistent with previous studies [9–11, 19], amphetamine led to a significant reduction in
[11C]FLB 457 BPND in five of the eight cortical regions of interest when data from all three
genotypes were included (Fig 2). No significant differences in amphetamine-induced
Table 2. [11C]FLB 457 baseline and post-amphetamine scan parameters.
Val/Val Val/Met Met/Met
(n = 11) (n = 14) (n = 6)
Baseline Amphetamine Baseline Amphetamine Baseline Amphetamine
Injected Dose (mCi) 7.4 ± 1.5 8.1 ± 0.6 7.8 ± 1.3 7.6 ± 1.3 7.6 ± 1.6 7.0 ± 2.4
Speciﬁc Activity (Ci mmol-1) 10752 ± 6754 9639 ± 3764 9925 ± 4753 8245 ± 4184 10863 ± 8124 8290 ± 6983
Injected Mass (μg) 0.4 ± 0.2 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.1 0.4 ± 0.2 0.4 ± 0.2
Free Fraction in Plasma (%) 36.3% ± 7.5% 35.0% ± 6.4% 38.4% ± 7.3% 37.6% ± 6.0% 38.9% ± 4.6% 35.8% ± 9.5%
Clearance (l h-1) 75 ± 19 72 ± 29 71 ± 28 74 ± 27 79 ± 14 84 ± 19
Cerebellum VND (mL cm
-3) 4.17 ± 0.69 3.94 ± 0.54 4.65 ± 1.31 4.47 ± 1.07 4.77 ± 0.98 4.30 ± 0.74
Amphetamine Level (ng mL-1) - 79.0 ± 12.51 - 76.5 ± 13.8 - 75.3 ± 8.62
VND Volume of distribution for nondispaceable tissue uptake
1 Amphetamine samples only available for n = 10 out of 11 subjects
2 Amphetamine samples only available for n = 5 out of 6 subjects
doi:10.1371/journal.pone.0157867.t002
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Fig 1. Baseline [11C]FLB 457 Binding Potential (BPND) in Genotyped Healthy Subjects. The bar graph
shows the lack of difference in D2/3 receptor availability in cortical regions of interest comparing Val/Val (white
bars), Val/Met (shaded bars), and Met/Met (black bars) genotyped healthy subjects.
doi:10.1371/journal.pone.0157867.g001
Fig 2. Amphetamine-Induced Displacement of [11C]FLB 457 Binding Potential. The bar graph shows [11C]FLB 457 BPND under baseline (white
bars) and post-amphetamine (black bars) conditions in n = 31 healthy subjects. Amphetamine led to a significant decrease in five of the eight cortical
regions of interest (* denotes p < 0.05, paired t-tests) consistent with previous reports [9–11].
doi:10.1371/journal.pone.0157867.g002
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Δ [11C]FLB 457 BPND were observed between the genotypes (data shown in Fig 3; linear mixed
model, effect of genotype, F (2, 28) = 0.12, p = 0.89; effect of region, F (7, 196) = 2.70, p = 0.01;
genotype x region interaction, F (14, 196) = 0.96, p = 0.50). The inclusion of smoking as a factor
in the model did not alter these results (genotype, p = 0.71; genotype region interaction,
p = 0.49). The use of alternative PET outcome measures such as ΔVT and ΔBPP showed no
significant effect for genotype consistent with that observed with ΔBPND. (data not shown).
ΔBPND derived using the simplified reference tissue method did not alter the results (genotype,
p = 0.55; region, p = 0.03; genotyperegion interaction, p = 0.62).
Discussion
The results of this study demonstrate the COMT Val158Met genotype is predictive of neither
D2/3 baseline receptor BPND nor amphetamine-induced ΔBPND in the cortical regions. The
failure to demonstrate a relationship between COMT Val158Met genotype and cortical D2/3
receptor BPND, which is consistent with a previously published report, was expected [6]. How-
ever, the failure to demonstrate a connection between COMT Val158Met genotype and cortical
dopamine transmission is surprising given that basic studies support such a relationship [7].
This is also inconsistent with the numerous human studies that link COMT genotype with pre-
frontal cortical dopamine-dependent behaviors such as cognition, aggression and impulsivity
[20–22]. The exact reasons that led to an inability to link COMT Val158Met genotype with
amphetamine-induced displacement of [11C]FLB 457 are unclear. One factor could be the rela-
tively high inter-individual variability associated with ΔBPND. This is likely due to the relatively
lower baseline D2/3 BPND and decreased dopamine released in response to amphetamine in the
cortex compared to that in the striatum [12]. This issue is highlighted in the literature by stud-
ies that have failed to displace the vivo binding of [11C]FLB 457 in the cortex following an
acute amphetamine challenge [23, 24]. Here, this is evident in Fig 3, where the standard devia-
tions for ΔBPND for the three different genotype groups in the cortical regions are high. For
example, in the dorsolateral prefrontal cortex, the amphetamine-induced ΔBPND in Met/Met
(-14 ± 21%) individuals is numerically, but not statistically, greater than that in Val/Val
(-6 ± 8%) and Val/Met (-6 ± 18%) individuals. However, to demonstrate whether this numeri-
cal difference reaches statistical significance in Met/Met compared to Val/Val and Val/Met, it
Fig 3. Amphetamine-Induced Δ[11C]FLB457 BPND in Genotyped Healthy Subjects. The bar graph
shows the amphetamine-induced reduction of [11C]FLB 457 BPND in cortical regions of interest comparing
Val/Val (white bars), Val/Met (shaded bars), and Met/Met (black bars) genotyped healthy subjects.
doi:10.1371/journal.pone.0157867.g003
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would require [11C]FLB 457-amphetamine data in 128 and 200 subjects respectively, as indi-
cated by power calculations (β = 0.8). The heterogeneity of the subject population (e.g., large
age range, gender, smoking status etc.,) and differences in scanning schedule (acquisition of
baseline and post-amphetamine scans on the same vs. different day) may have also contributed
to the variable Δ in BPND. Another factor that may have contributed to the inability to demon-
strate an effect for COMT genotype on ΔBPND in our paradigm is the fact that the half-life for
amphetamine-induced dopamine release is relatively prolonged in the cortex [25]. Studies have
shown that the half-life (t1/2) for dopamine released in the cortex is ~ 2.5 hours for intravenous
amphetamine, which peaks immediately (< 5 minutes) in the plasma. This is relevant because
the timing of the [11C]FLB 457 post-amphetamine scan (i.e., three hours after the oral amphet-
amine administration) in our studies was designed to capture the peak dopamine release that
follows the peak amphetamine plasma level (~ 3–4 hours), and not necessarily the clearance,
which is measured following several half-lives. [11C]FLB 457 PET studies measuring time to
restore baseline BPND rather than the magnitude Δ in BPND following an acute amphetamine
challenge might be more relevant in detecting a difference in the clearance of dopamine as
influenced by COMT Val158Met genotypes. It is also possible that alpha-methyl-para-tyrosine
(AMPT) induced dopamine depletion PET studies that measure baseline dopamine levels may
be more successful in detecting an effect for the COMT genotype. However, measuring baseline
dopamine levels in the cortex with such an imaging paradigm has been unsuccessful due to
technical challenges [26, 27]. Consistent with this is the notion that the COMT genotype influ-
ences tonic more than phasic dopamine levels [28]. Such a line of reasoning would explain the
D1 receptor findings reported with COMT genotype because D1 receptors that are located in
the extra synaptic space likely reflect slower adaptations, including changes in gene transcrip-
tion in response to chronically altered tonic dopamine levels. It would also explain the lack of a
relationship between COMT genotype and amphetamine-induced dopamine release, which is
likely more reflective of the phasic DA release caused by behaviors.
To summarize, the strengths of this study include the use of a well-validated imaging para-
digm to measure dopamine release in the cortex and inclusion of a reasonable sample size by
PET study standards. The weaknesses of the study include increased variability associated with
the dopamine release outcome measure ΔBPND and questions related to how well the amphet-
amine-induced dopamine release paradigm captures the effect of the COMT genotypes on
dopamine clearance. In conclusion, we were not able to demonstrate an effect for the COMT
Val158Met genotype on either cortical D2/3 receptor BPND or amphetamine-induced dopa-
mine transmission.
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